Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05107856 · ClinicalTrials.gov registry record · Phase 1
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
A Phase 1 study, sponsored by Prelude Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05107856 is a Phase 1 study that was terminated before completion, run by Prelude Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT05107856, a Phase 1 study, was terminated before completion, sponsored by Prelude Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies. The purpose of this study is to evaluate the safety and tolerability of PRT1419 monotherapy and in combination with either azacitidine or venetoclax, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG PRT1419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2024-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107856
The ClinicalTrials.gov registry entry for NCT05107856 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT05107856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05107856 about?
NCT05107856 is a clinical study titled "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies". This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies. The purpose of this study is to evaluate the safety and tolerability of PRT1419 monotherapy and in combination with eithe...
What is the current status of trial NCT05107856?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-03-22. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT05107856?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), PRT1419 (DRUG).
Who is sponsoring clinical trial NCT05107856?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.